| Literature DB >> 8842987 |
M C Meyohas1, J L Meynard, D Bollens, P Roux, A M Deluol, J L Poirot, W Rozenbaum, C Mayaud, J Frottier.
Abstract
Amphotericin B, alone or combined with flucytosine, is the reference curative treatment for neuromeningeal cryptococcosis associated with the acquired immune deficiency syndrome (AIDS). Treatment of non-meningeal forms is less well standardized. Out of 75 human immunodeficiency virus (HIV)-infected patients with cryptococcosis, 16 had no meningeal involvement. One died before receiving any treatment, another received amphotericine B and recovered, and the remaining 14 received curative therapy with fluconazole (200-400 mg/day); 11 of the latter entered complete remission, while three deteriorated during the first week of treatment but recovered on amphotericin B combined, in two cases, with fluconazole. Only one relapse occurred during maintenance treatment with low-dose fluconazole (100 mg/day). No adverse effects of fluconazole treatment were observed. One of the patients on amphotericin B developed acute renal impairment requiring drug withdrawal. These results suggest that first-line fluconazole therapy is effective and well tolerated in patients with AIDS-associated non meningeal cryptococcosis.Entities:
Mesh:
Substances:
Year: 1996 PMID: 8842987 DOI: 10.1016/s0163-4453(96)92624-9
Source DB: PubMed Journal: J Infect ISSN: 0163-4453 Impact factor: 6.072